We are international

Myeloma Minute
April 16, 2015
April 16, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF


This week's question: When will the first monoclonal antibody be approved?

Multiple Myeloma Bone Study

Ixazomib Citrate Maintenance Therapy After ASCT

Ixazomib in Combination with LenDex in Newly Diagnosed Myeloma

Ixazomib in Newly Diagnosed and/or Relapsed/Refractory Myeloma

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events

Saturday, April 25, 2015
7th Annual Miles for Myeloma 5K Run/Walk
Philadelphia, Pennsylvania


Saturday, May 2, 2015
Ava & Cece's Race to Beat Myeloma
Wheaton, Maryland


Sunday, May 3, 2015
Flying Pig Marathon
Cincinnati, Ohio


Thursday, May 7, 2015
Dr. Matt Mumber, Living Well With Myeloma Teleconference
Nationwide, 4PM PST - 7PM EST

Saturday, May 9, 2015
Myeloma Center Workshop
Seattle, Washington


Watch the IMF Mambo for Myeloma & Support This Challenge



How to Be Safer as You Live Longer: A Patient Checklist


Effective new therapies have extended the lives of many myeloma patients. But with that wonderful benefit comes the need to stay vigilant about disease and treatment side effects, as well as health challenges facing us all as we age. In his blog this week, IMF Chairman Dr. Brian Durie offers an awareness checklist for patients. To read CLICK HERE.


Bristol-Myers Squibb Announces Opening of Expanded Access Program for Elotuzumab


Bristol-Myers Squibb (BMS) has opened an expanded access protocol for its monoclonal antibody elotuzumab in combination with Revlimid® and dexamethasone. Expanded access is a process regulated by the Food and Drug Administration (FDA) that allows manufacturers to provide investigational new drugs to patients with serious diseases or conditions who cannot participate in a clinical trial. ?While data from a large, phase III randomized trial comparing elotuzumab plus Rev/dex versus Rev/dex alone is eagerly anticipated, in the interim patients may now enroll at an available site for access to this new combination therapy. The first 5 of a planned 50-60 sites are now enrolling patients with myeloma that has relapsed after 1-3 prior treatments. For eligibility criteria and site information CLICK HERE.


Hot Off the Presses: Read the Latest Issue of Myeloma Today


The spring issue of ‎Myeloma Today spotlights our work in the four key areas of IMF's mission—advocacy, research, education and support—as we bring everyone together in #‎OneMyelomaNation! Learn about the launch of IMF’s Oral History Project, read a recap of myeloma treatment progress here and in Europe, find out how we’re helping veterans with myeloma and more! CLICK HERE to download.


Myeloma Comic Book Is Creative Form of Therapy


What began as an artistic outlet to help artist Sarita Johnson deal with anxiety when her partner was diagnosed with myeloma in 2010 has become a valuable coping tool for others. Sarita Johnson, a graphic novelist, says she created “The Donkey in Albany: A Year with Multiple Myeloma” because she thought that “documenting the experience would be good therapy.” To read more CLICK HERE.


Resources for Cancer Caregivers All in One Place


A myeloma diagnosis affects not only the patient who receives it, but also friends, family members, and caregivers – who often feel overwhelmed by both the necessary lifestyle adjustments and the enormous amount of information they need. Now some key organizations have teamed up to form Help For Cancer Caregivers, a valuable resource for anyone responsible for myeloma patients. CLICK HERE to view the website.

Help Canadians Living with Myeloma


Myeloma Canada, an international affiliated partner of the IMF, is participating in a Canadian government funding review for the treatment of myeloma with lenalidomide (Revlimid®) and needs our help. To participate in this review process, Myeloma Canada needs to gather information from myeloma patients and caregivers who have experience with lenalidomide as a first-line therapy. If you or someone you care for has used lenalidomide as a first-line therapy, please take 10 minutes to complete this survey. The close date for the survey is Friday, April 24th, 2015. Thank you!

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe

 related articles